Introduction Interindividual differences in drug response are a frequent clinical challenge
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …

Background Platinum-based chemotherapy bring severe hematological toxicity that can lead
to dose reduction or discontinuation of therapy. Genetic variations have been reported to …

Pancreatic malignancy is the fourth cause of cancer-related death in Western countries and
is predicted to become the second leading cause of cancer-related mortality by 2030. The …

Platinum-based chemotherapy regimens have been proven to be effective in various
cancers; however, considerable toxicities may develop and can even lead to treatment …

Background: Platinum-based agents, including cisplatin, carboplatin, and oxaliplatin, are
indispensable for the treatment of lung cancer. The development of toxicity frequently …

Currently, there is a growing concern surrounding the treatment of cancer, a formidable
disease. Pharmacogenomics and personalized medicine have emerged as significant areas …

Purpose Resistance to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and
cyclophosphamide (FAC) in some patients with locally advanced breast cancer remains one …

Severe gastrointestinal (GI) toxicity is a common side effect after platinum-based
chemotherapy. The incidence and severity of GI toxicity vary among patients with the same …

Background Hematotoxicity, including severe myelosuppression, is a common adverse drug
reaction (ADR) during platinum‐based treatment for oesophageal cancer (EC). Purpose The …

Head and neck cancer (HNC) is the set of malignant tumours located in the upper
aerodigestive tract and the therapy is based on radiotherapy concomitant with highdose …